Consulter la liste des posters présentés par les

Liste des posters présentés par les médecins de l’Institut Curie au congrès de San Antonio
Long term survival of locally advanced breast cancers (LABC) treated with neoadjuvant treatment,
results of a multicenter randomised phase II study (Remagus 02 trial)
Giacchetti S, Hamy-Petit A-S, Delaloge S, Brain E, Berger F, Mathieu M-C, de Cremoux P, Bertheau P,
Guinebretière J-M, Saghatchian M, Tembo O, Marty M, Pierga J-Y.
Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France, Gustave Roussy,
Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital
Saint Louis, APHP, Paris, France; Molecular Oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH,
Hôpital Saint Louis, Paris, France.
Initial circulating tumor cell count and venous thrombosis-free interval in the course of metastatic
breast cancer
Beinse G, Berger F, Cottu PH, Dujaric M-E, Kriegel I, Guilhaume M-N, Dieras V, Beuzeboc P, Pierga J-Y,
Bidard F-C. Institut Curie, Paris, France.
T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor
cells: Current status of the CirCe T-DM1 phase II trial
Bidard F-C, Romieu G, Jacot W, Cottu P, Dieras V, Lerebours F, Servent V, Luporsi E, Lortholary A,
Tubiana-Mathieu N, Espie M, Bollet M, Bourgeois H, Renaud N, Pelissier S, Armanet S, Baeten K,
Pierga J-Y.
Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar
Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre
Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis
University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France;
Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium.
Ki67 cut-off point to predict the benefit of adjuvant chemotherapy in ER+ HER2- breast cancer
patients
Rouzier R, Rossi L, Lerebours F, Savignoni A, Falcou M-C, Bonneau C, Pierga J-Y, Guinebretière J-M.
Institut Curie, Saint-Cloud - Paris, France
Hydrosorb® versus control (water based spray) in the management of radio-induced skin toxicity:
Results of multicentre controlled randomized trial
Bazire L, Fromentin I, Diallo A, de Lalande B, Pernin V, Dendale R, Fourquet A, Savignoni A, Kirova Y.
Institut Curie, Paris, Ile-de-France, France, Metropolitan; Institut Curie, Saint-Cloud, Ile-de-France,
France, Metropolitan.
Prognostic and predictive value of COX2 in breast cancer, correlation with PIK3CA mutations
Tury S, Becette V, Assayag F, Vacher S, Marangoni E, Bièche I, Lerebours F, Callens C.
Institut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France.
Development of individual adjuvant chemotherapy benefit estimating program for breast cancer
patients management
Rouzier R, Stevens D, Bonneau C, Falcou M-C, Hequet D, Pierga J-Y, Lerebours F.
Institut Curie, Saint-Cloud - Paris, France.
New insights on HER2 amplification from the constitutional and somatic standpoints: Results from
the ICGC and SIGNAL/Phare studies
Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier A-S,
Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari
A.
Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz,
Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val
d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer
Center, Marseille, France.
DI study: Decision impact of the NanoString® Technologies Prosigna™ in early breast cancers
Hequet D, Guinebretière J-M, Lerebours F, Roulot A, Callens C, Gentien D, Penault-LLorca F,
Zilberman S, Salmon R, Foa C, Berseneff H, Huchon C, Katz G, MacDonald M, Morel P, Bieche I, Dubot
C, Rouzier R.
Institut Curie-Centre René Huguenin, St Cloud, France; Institut Curie, Paris, France; Centre Jean
Perrin, Clermont-Ferrand, France; Tenon Hospital, Paris, France; Private Hospital Les Peupliers, Paris,
France; Private Hospital Clairval, Marseille, France; René Dubos Hospital, Pontoise, France; Poissy-St
Germain Hospital, Poissy, France; Groupe Général de Santé, Paris, France; NanoString Technologies,
Seattle; Equipe d'Accueil 7285, Risk and Safety in Clinical Medicine for Women and Perinatal Health,
University Versailles-Saint-Quentin, Montigny-le-Bretonneux, France.
Optisoins01: Optimizing the patient-breast cancer care pathway; An observational multicentric
prospective study
Héquet D, Baffert S, Hoang HL, Brédart A, Asselain B, Alran S, Berseneff H, Huchon C, Trichot C,
Combes A, Alves K, Koskas M, Nguyen T, Roulot A, Rouzier R.
Institut Curie-Centre René Huguenin, St Cloud, France; Equipe d'Accueil 7285, Risk and Safety in
Clinical Medicine for Women and Perinatal Health, University Versailles-Saint-Quentin, Montigny-leBretonneux, France; Institut Curie, Paris, France; René Dubos Hospital, Pontoise, France; Poissy-St
Germain Hospital, Poissy, France; Antoine Béclère Hospital, Clamart, France; André Mignot Hospital,
Versailles, France; Argenteuil Hospital, Argenteuil, France; Bichat Hospital, Paris, France; Louis
Mourier Hospital, Colombes, France.